Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P00492 (
hypoxanthine-guanine phosphoribosyltransferase
)
2,385
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
We have constructed Chinese hamster V79-derived cell lines (V79-rSULT1B1-A and -B) that express rat
sulfotransferase 1B1
(rSULT1B1). Sulfotransferase activity towards 1-naphthol was 1020 +/- 220 pmol/min/mg cytosolic protein in V79-rSULT1B1-A cells and 57 +/- 9 pmol/ min/mg in V79-rSULT1B1-B cells. These activities were similar over 100 population doublings and at varying cell densities. Immunostaining indicated a cytoplasmatic localization of rSULT1B1. Expression usually was homogeneous within colonies but showed some variation between colonies. The level of rSULT1B1 protein in V79-rSULT1B1-B cells was similar to that in rat liver but higher than in colon mucosa. The cytotoxicity of the benzylic alcohols 4H-cyclopenta[def]chrysen-4-ol and 6-hydroxymethylbenzo-[a]pyrene was enhanced >100-fold in V79-rSULT1B1-A cells compared with SULT-deficient cells (V79p). Likewise, these compounds showed mutagenic effects (at the
hprt
locus) in V79-rSULT1B1-A cells starting at a concentration of 0.02 and 0.01 micro M, respectively, but were inactive in V79p cells even at a concentration of 1 micro M. The cell line with the lower expression level, V79-rSULT1B1-B, showed only marginal toxification of the compounds investigated, indicating an important role of the expression level in the test system. A thoroughly characterized mammalian cell system, including positive controls, is now available for studying rSULT1B1-mediated bioactivation of promutagens and protoxicants.
...
PMID:Stable expression of rat sulfotransferase 1B1 in V79 cells: activation of benzylic alcohols to mutagens. 1241 36
2-Amino-3-methyl-9H-pyrido[2,3-b]indole (MeAalphaC) and some metabolites were investigated for mutagenicity in mammalian cell lines and bacterial strains engineered for the expression of human enzymes. MeAalphaC induced gene mutations (studied at the
hprt
locus) in Chinese hamster V79-derived cells co-expressing cytochrome (CYP) 1A2 and sulphotransferase (SULT) 1A1 even at a concentration of 30 nM, but was inactive in cells co-expressing CYP1A2 and N-acetyltransferase (NAT) 1 or 2. MeAalphaC, tested in the presence of rat liver post-mitochondrial fraction, showed strongly enhanced mutagenicity in a Salmonella typhimurium strain expressing human SULT1A1 compared with the control (recipient) strain TA1538/1,8-DNP (deficient in endogenous acetyltransferase). Mutagenicity was also enhanced, although to a lesser extent, when NAT2 was expressed in the latter strain. The metabolite, 2-hydroxylamino-3-methyl-9H-pyrido[2,3-b]indole (N-OH-MeAalphaC) was a direct mutagen to strains TA1538 and TA1538/ 1,8-DNP. This mutagenicity was strongly enhanced in corresponding strains expressing SULT1A1. A moderate enhancement was observed when SULT1A2,
SULT1B1
, SULT1C2 or NAT2 were expressed in strain TA1538. The remaining enzymes studied (SULT1A3, 1C1, 1E1, 2A1, 2B1a, 2B1b, 4A1 and NAT1) did not indicate any activation of N-OH-MeAalphaC. Preliminary mutagenicity experiments in SULT-expressing S.typhimurium strains were conducted with other hydroxylated metabolites of MeAalphaC. The phenols, 6- and 7-hydroxy-MeAalphaC, were inactive under the conditions studied. The benzylic alcohol, 2-amino-3-hydroxymethyl-9H-pyrido[2,3-b]indole, was mutagenic in a strain expressing SULT1A1, but its activity was much weaker than that of N-OH-MeAalphaC. Thus, N-hydroxylation (e.g. mediated by CYP1A2) and sulpho conjugation (primarily mediated by SULT1A1) was the dominating activation pathway of MeAalphaC in model systems engineered for human enzymes. Some other SULT forms as well as NAT2 were also capable of activating N-OH-MeAalphaC, although with much lower efficiency than SULT1A1. Another minor activation pathway involved benzylic hydroxylation followed by sulpho conjugation by SULT1A1.
...
PMID:Bioactivation of the heterocyclic aromatic amine 2-amino-3-methyl-9H-pyrido [2,3-b]indole (MeAalphaC) in recombinant test systems expressing human xenobiotic-metabolizing enzymes. 1472 82